1xbet 카지노

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has completed 1xbet 카지노 acquisition of Jnana 1xbet 카지노rapeutics Inc. (Jnana), based in Boston, Massachusetts. Jnana has become a direct subsidiary of Otsuka America, Inc. (OAI), which is a fully owned subsidiary of Otsuka.

Based on 1xbet 카지노 terms of 1xbet 카지노 agreement signed in August of this year, Otsuka paid (U.S.) 0 million to 1xbet 카지노 shareholders of Jnana as consideration for 1xbet 카지노 acquisition of all outstanding shares of 1xbet 카지노 company. In addition, Otsuka may pay up to (U.S.) 5 million to Jnana shareholders in development and regulatory milestone payments based on 1xbet 카지노 progress of future development products.

Jnana utilizes an innovative drug discovery approach, 1xbet 카지노 Reactive Affinity Probe Interaction Discovery (RAPID) platform, for a variety of drug targets on which it has been difficult to obtain small-molecule drugs through traditional screening systems. With its focus on identifying first-in-class compounds for autoimmune and rare diseases, Jnana is in a unique competitive position. In 1xbet 카지노 autoimmune disease field, 1xbet 카지노 company is pursuing small molecule drug discovery for highly validated targets such as interferon regulatory factor 3 (IRF3), a master transcription factor for 1xbet 카지노 production of interferon.

In addition, using this drug discovery technology, Jnana developed JNT-517, an oral small-molecule inhibitor of a protein that regulates phenylalanine reabsorption in 1xbet 카지노 kidneys, and is conducting a Phase 1b/2 study in patients with phenylketonuria (PKU), a rare, inherited metabolic disorder in which symptoms usually begin to appear in infancy. Earlier this month, Jnana presented 1xbet 카지노 results of 1xbet 카지노 Phase 1b/2 study at 1xbet 카지노 Society for 1xbet 카지노 Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium . In addition to data for 1xbet 카지노 75-mg dose, new data for 1xbet 카지노 150-mg dose (both twice daily) were disclosed at this conference presentation.

Summary 1xbet 카지노 P1b/2 study interim data

• A strong reduction in blood phenylalanine levels was observed within one week of 1xbet 카지노 start of dosing, regardless of 1xbet 카지노 severity of 1xbet 카지노 disease or non-responsiveness to existing treatments
• Twice-daily oral treatment with JNT-517 at 150-mg dose delivered statistically significant mean blood phenylalanine reduction 1xbet 카지노 60% versus baseline in individuals with PKU
• JNT-517 was safe and well tolerated with no serious adverse events observed

（reference :https://www.jnanatx.com/jnt-517-a-first-1xbet 카지노-class-slc6a19-1xbet 카지노hibitor/）

JNT-517 has received orphan drug designation and rare pediatric disease designation from 1xbet 카지노 U.S. FDA and orphan designation from 1xbet 카지노 European Medicines Agency (EMA) for 1xbet 카지노 treatment of PKU. JNT-517 has also been granted eligibility for 1xbet 카지노 EMA PRIME (PRIority MEdicines) scheme for 1xbet 카지노 treatment of hyperphenylalaninemia. Based on 1xbet 카지노 data from this Phase 1b/2 study, 1xbet 카지노 company is currently engaging in discussions with U.S. and European regulatory authorities and plans to initiate a Phase 3 study in early 2025.